文献速递复苏、休克与脓毒症心脑血管急症

替奈普酶院前溶栓用于院外心脏骤停:一项回顾性队列研究

Prehospital thrombolysis with tenecteplase in out-of-hospital cardiac arrest: a retrospective cohort study.
PubMed 文献 · Scand J Trauma Resusc Emerg Med · 2025-11-26
一句话结论在疑似血栓栓塞性院外心脏骤停患者中,院前替奈普酶溶栓与30天生存率和ROSC降低相关,不支持其常规院前经验性使用。

该回顾性队列研究基于区域心脏骤停登记数据库,纳入2829例成人院外心脏骤停(OHCA)病例,其中171例在院前接受替奈普酶溶栓。主要终点为30天生存率,溶栓组为4%,对照组为10%;校正混杂因素后,溶栓组30天生存的比值显著降低(OR 0.08,95%CI 0.04-0.19),达到ROSC的比值亦显著降低(OR 0.21,95%CI 0.14-0.33)。可除颤心律(OR 15.89)和目击骤停(OR 1.99)是生存的强独立预测因素。作者认为,基于疑似血栓栓塞病因的经验性院前溶栓缺乏持续获益,并对其在无明确诊断下的常规院前使用提出质疑。

要点

  • 在2829例成人OHCA中,171例院前接受替奈普酶溶栓,30天生存率溶栓组4% vs 对照组10%。
  • 校正混杂因素后,溶栓组30天生存的OR为0.08(95%CI 0.04-0.19),ROSC的OR为0.21(95%CI 0.14-0.33)。
  • 可除颤心律(OR 15.89)和目击骤停(OR 1.99)是生存的强独立预测因素。
  • 作者认为,基于疑似血栓栓塞病因的经验性院前溶栓缺乏持续获益,并对其无明确诊断下的常规院前使用提出质疑。

适用人群与场景

  • 成人院外心脏骤停(OHCA)患者,来自区域心脏骤停登记数据库,共2829例。
  • 其中171例在院前接受替奈普酶溶栓,其余为对照组。

研究设计与关键结果

  • 研究类型为回顾性队列研究,基于区域心脏骤停登记数据库,纳入2829例成人OHCA,其中171例院前接受替奈普酶溶栓。
  • 主要终点30天生存率:溶栓组4% vs 对照组10%。
  • 校正混杂因素后,溶栓组30天生存的OR为0.08(95%CI 0.04-0.19),ROSC的OR为0.21(95%CI 0.14-0.33)。
  • 可除颤心律(OR 15.89)和目击骤停(OR 1.99)是生存的强独立预测因素。
  • 模型拟合度中等(McFadden's R² = 0.27)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,基于疑似血栓栓塞病因的经验性院前替奈普酶溶栓缺乏持续获益,并对其在无明确诊断下的常规院前使用提出质疑。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The role of thrombolysis in out-of-hospital cardiac arrest (OHCA) remains uncertain, with limited evidence of benefit. This study evaluated whether prehospital administration of Tenecteplase improves outcomes in patients with presumed thromboembolic OHCA.

METHODS: A retrospective cohort study was conducted using a regional cardiac arrest registry comprising 2,829 adult OHCA cases. Of these, 171 patients received Tenecteplase in the prehospital setting. Logistic regression was used to assess the association between thrombolysis and two outcomes: 30-day survival (primary) and return of spontaneous circulation (ROSC) at hospital arrival (secondary), adjusting for relevant confounders.

RESULTS: Thirty-day survival was 4% in the thrombolysis group versus 10% in controls. Adjusted odds of survival were significantly lower with thrombolysis (OR 0.08, 95% CI 0.04-0.19), as were odds of achieving ROSC (OR 0.21, 95% CI 0.14-0.33). Shockable rhythm (OR 15.89) and witnessed arrest (OR 1.99) were strong independent predictors of survival. Model fit was moderate (McFadden's R² = 0.27).

CONCLUSION: Prehospital thrombolysis with Tenecteplase was not associated with improved survival or ROSC in OHCA and may be linked to worse outcomes. These findings highlight a lack of sustained benefit associated with empiric thrombolysis based on suspected thromboembolic cause in OHCA, and raise questions about its routine prehospital use without definitive diagnosis.

来源:Scand J Trauma Resusc Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Cowley A, Cody D, Jaquet E, et al. Prehospital thrombolysis with tenecteplase in out-of-hospital cardiac arrest: a retrospective cohort study. Scand J Trauma Resusc Emerg Med. 2025. PMID: 41299585. doi:10.1186/s13049-025-01522-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。